Unlocked

Citations 51-60 of 64 total displayed.

Extended reports
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis

J C Davis, Jr, D M van der Heijde, J Braun, M Dougados, D O Clegg, A J Kivitz, R M Fleischmann, R D Inman, L Ni, S-L Lin, and W H Tsuji
Ann Rheum Dis 2008 67: 346 -352; published online before print as 10.1136/ard.2007.078139 [Abstract] [Full text] [PDF] [Request Permissions]  

Extended reports
Associations between Human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study

E W Karlson, L B Chibnik, J Cui, R M Plenge, R J Glass, N E Maher, A Parker, R Roubenoff, E Izmailova, J S Coblyn, M E Weinblatt, and N A Shadick
Ann Rheum Dis 2008 67: 358 -363; published online before print as 10.1136/ard.2007.071662 [Abstract] [Full text] [PDF] [Request Permissions]  

Extended reports
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, D Isenberg, C G M Kallenberg, M Khamashta, J C Piette, M Schneider, J Smolen, G Sturfelt, A Tincani, R van Vollenhoven, C Gordon, and D T Boumpas
Ann Rheum Dis 2008 67: 195 -205; published online before print as 10.1136/ard.2007.070367 [Abstract] [Full text] [PDF] [Request Permissions]  

Extended reports
The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome

H Naseem, W Thomson, A Silman, J Worthington, D Symmons, and A Barton
Ann Rheum Dis 2008 67: 251 -255; published online before print as 10.1136/ard.2007.071894 [Abstract] [Full text] [PDF] [Request Permissions]  

Extended reports
Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis

Marja-Kaisa Koivula, Markku Heliövaara, Jarmo Ramberg, Paul Knekt, Harri Rissanen, Timo Palosuo, and Juha Risteli
Ann Rheum Dis 2007 66: 1450 -1455; published online before print as 10.1136/ard.2006.062919 [Abstract] [Full text] [PDF] [Request Permissions]  

Extended reports
The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis

Hector Chinoy, Noreen Fertig, Chester V Oddis, William E R Ollier, and Robert G Cooper
Ann Rheum Dis 2007 66: 1345 -1349; published online before print as 10.1136/ard.2006.068502 [Abstract] [Full text] [PDF] [Request Permissions]  

Extended reports
Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent

J Adriaansen, M Khoury, C J de Cortie, F J Fallaux, P Bigey, D Scherman, D J Gould, Y Chernajovsky, F Apparailly, C Jorgensen, M J B M Vervoordeldonk, and P P Tak
Ann Rheum Dis 2007 66: 1143 -1150; published online before print as 10.1136/ard.2006.064519 [Abstract] [Full text] [PDF] [Request Permissions]  

Extended reports
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

Norihiro Nishimoto, Jun Hashimoto, Nobuyuki Miyasaka, Kazuhiko Yamamoto, Shinichi Kawai, Tsutomu Takeuchi, Norikazu Murata, Désirée van der Heijde, and Tadamitsu Kishimoto
Ann Rheum Dis 2007 66: 1162 -1167; published online before print as 10.1136/ard.2006.068064 [Abstract] [Full text] [PDF] [Request Permissions]  

Extended reports
Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial

Matthias Rother, Bernard J Lavins, Werner Kneer, Klaus Lehnhardt, Egbert J Seidel, and Stefan Mazgareanu
Ann Rheum Dis 2007 66: 1178 -1183; published online before print as 10.1136/ard.2006.065128 [Abstract] [Full text] [PDF] [Request Permissions]  

Extended reports
All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

Loreto Carmona, Miguel Ángel Descalzo, Eva Perez-Pampin, Dolores Ruiz-Montesinos, Alba Erra, Tatiana Cobo, Juan J Gómez-Reino on behalf of the BIOBADASER and EMECAR Groups
Ann Rheum Dis 2007 66: 880 -885; published online before print as 10.1136/ard.2006.067660 [Abstract] [Full text] [PDF] [Request Permissions]